Symbols / QURE Stock $18.03 +2.79% uniQure N.V.

Healthcare • Biotechnology • Netherlands • NMS
QURE (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Matthew Craig Kapusta CPA
Exch · Country NMS · Netherlands
Market Cap 1.13B
Enterprise Value 1.04B
Income -198.97M
Sales 16.10M
FCF (ttm) -106.76M
Book/sh 3.19
Cash/sh 9.96
Employees 221
Insider 10d —
IPO Feb 05, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -6.65
PEG —
P/S 70.03
P/B 5.65
P/C —
EV/EBITDA -6.34
EV/Sales 64.69
Quick Ratio 9.99
Current Ratio 10.43
Debt/Eq 269.78
LT Debt/Eq —
EPS (ttm) -3.46
EPS next Y -2.71
EPS Growth —
Revenue Growth 6.60%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-03-02
ROA -16.21%
ROE -207.10%
ROIC —
Gross Margin 0.00%
Oper. Margin -9.01%
Profit Margin 0.00%
Shs Outstand 62.53M
Shs Float 49.29M
Insider Own 5.61%
Instit Own 99.70%
Short Float 17.95%
Short Ratio 6.20
Short Interest 11.10M
52W High 71.50
vs 52W High -74.78%
52W Low 8.73
vs 52W Low 106.53%
Beta 0.75
Impl. Vol. 1.49%
Rel Volume 0.32
Avg Volume 3.18M
Volume 1.01M
Target (mean) $38.47
Tgt Median $35.25
Tgt Low $9.04
Tgt High $96.10
# Analysts 11
Recom Buy
Prev Close $17.54
Price $18.03
Change 2.79%
About

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$38.47
Mean price target
2. Current target
$18.03
Latest analyst target
3. DCF / Fair value
$-30.73
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$18.03
Low
$9.04
High
$96.10
Mean
$38.47

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-20 main Goldman Sachs Neutral → Neutral $10
2026-03-23 main Barclays Equal-Weight → Equal-Weight $25
2026-03-11 up Mizuho Neutral → Outperform $35
2026-03-10 reit HC Wainwright & Co. Buy → Buy $70
2026-03-09 main Chardan Capital Buy → Buy $31
2026-03-09 up RBC Capital Sector Perform → Outperform $35
2026-03-09 up Wells Fargo Equal-Weight → Overweight $60
2026-03-03 main Goldman Sachs Neutral → Neutral $9
2026-03-03 down Wells Fargo Overweight → Equal-Weight $15
2026-03-03 main Chardan Capital Buy → Buy $16
2026-03-03 down Mizuho Outperform → Neutral $12
2026-03-02 up Cantor Fitzgerald Overweight → Neutral $9
2026-02-24 init Wolfe Research — → Peer Perform —
2026-02-10 reit HC Wainwright & Co. Buy → Buy $70
2026-01-28 init Barclays — → Equal-Weight $31
2025-12-11 main Stifel Buy → Buy $40
2025-12-09 main Mizuho Outperform → Outperform $33
2025-12-04 main Chardan Capital Buy → Buy $53
2025-11-12 main Wells Fargo Overweight → Overweight $60
2025-11-11 main Chardan Capital Buy → Buy $53
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-04 KAPUSTA MATTHEW C Chief Executive Officer — 70,600 $0.00 $0
2026-03-04 KAPUSTA MATTHEW C Chief Executive Officer — 14,581 $9.06 $132,104
2026-03-04 KLEMT CHRISTIAN Chief Financial Officer — 39,600 $0.00 $0
2026-03-04 KLEMT CHRISTIAN Chief Financial Officer — 12,000 $9.06 $108,720
2026-03-04 POTTS JEANNETTE Officer — 35,400 $0.00 $0
2026-03-04 POTTS JEANNETTE Officer — 3,412 $9.06 $30,913
2026-03-04 ABI-SAAB WALID Officer — 41,700 $0.00 $0
2026-03-04 ABI-SAAB WALID Officer — 808 $9.06 $7,320
2026-03-04 O'KEEFE KYLIE Officer — 19,800 $0.00 $0
2026-03-02 KAPUSTA MATTHEW C Officer and Director — 34,437 $9.95 $342,648
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
16.10
-40.64%
27.12
+71.17%
15.84
-85.12%
106.48
Operating Revenue
16.10
-40.64%
27.12
+71.17%
15.84
-85.12%
106.48
Cost Of Revenue
1.69
-90.80%
18.33
+34.48%
13.63
+307.66%
3.34
Reconciled Cost Of Revenue
1.69
-78.37%
7.80
+106.30%
3.78
+13.04%
3.34
Gross Profit
14.41
+63.92%
8.79
+296.93%
2.21
-97.85%
103.14
Operating Expense
202.24
+5.90%
190.97
-32.92%
284.70
+15.08%
247.39
Research And Development
140.67
-2.16%
143.78
-33.08%
214.86
+8.74%
197.59
Selling General And Administration
65.34
+28.92%
50.68
-30.65%
73.08
+33.60%
54.70
General And Administrative Expense
65.34
+28.92%
50.68
-30.65%
73.08
+33.60%
54.70
Salaries And Wages
35.04
+5.32%
33.27
-20.38%
41.78
+14.34%
36.54
Other Gand A
28.50
+77.57%
16.05
-47.18%
30.39
+75.34%
17.33
Other Operating Expenses
-5.68
-1.41%
-5.60
-5.84%
-5.29
+13.00%
-6.08
Total Expenses
203.93
-2.57%
209.30
-29.84%
298.33
+18.98%
250.73
Operating Income
-187.83
-3.10%
-182.18
+35.51%
-282.49
-95.84%
-144.25
Total Operating Income As Reported
-185.35
-0.57%
-184.29
+34.85%
-282.87
-97.59%
-143.16
EBITDA
-116.59
+27.47%
-160.75
+36.49%
-253.10
-134.31%
-108.02
Normalized EBITDA
-148.72
+0.96%
-150.16
+40.00%
-250.26
-86.69%
-134.05
Reconciled Depreciation
14.76
+16.76%
12.64
+6.23%
11.90
+39.39%
8.54
EBIT
-131.35
+24.25%
-173.39
+34.57%
-265.00
-127.36%
-116.56
Total Unusual Items
32.13
+403.70%
-10.58
-272.27%
-2.84
-110.92%
26.04
Total Unusual Items Excluding Goodwill
32.13
+403.70%
-10.58
-272.27%
-2.84
-110.92%
26.04
Special Income Charges
6.00
+8319.18%
-0.07
+79.78%
-0.36
0.00
Restructuring And Mergern Acquisition
0.00
-100.00%
1.22
+238.78%
0.36
0.00
Net Income
-198.97
+16.94%
-239.56
+22.34%
-308.48
-143.30%
-126.79
Pretax Income
-193.34
+18.47%
-237.13
+22.65%
-306.56
-139.01%
-128.26
Net Non Operating Interest Income Expense
-45.03
-6.38%
-42.33
-92.43%
-22.00
-98.24%
-11.10
Interest Expense Non Operating
61.99
-2.74%
63.74
+53.38%
41.56
+255.07%
11.70
Net Interest Income
-45.03
-6.38%
-42.33
-92.43%
-22.00
-98.24%
-11.10
Interest Expense
61.99
-2.74%
63.74
+53.38%
41.56
+255.07%
11.70
Interest Income Non Operating
16.97
-20.77%
21.41
+9.47%
19.56
+3112.15%
0.61
Interest Income
16.97
-20.77%
21.41
+9.47%
19.56
+3112.15%
0.61
Other Income Expense
39.51
+413.08%
-12.62
-507.95%
-2.08
-107.65%
27.12
Other Non Operating Income Expenses
7.38
+461.73%
-2.04
-366.45%
0.77
-29.53%
1.09
Gain On Sale Of Security
26.13
+348.70%
-10.51
-323.50%
-2.48
-109.53%
26.04
Gain On Sale Of Business
0.00
-100.00%
1.15
0.00
0.00
Tax Provision
5.63
+131.82%
2.43
+26.44%
1.92
+230.68%
-1.47
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+2151.11%
0.00
Tax Effect Of Unusual Items
8.29
+403.70%
-2.73
-272.27%
-0.73
-345.73%
0.30
Net Income Including Noncontrolling Interests
-198.97
+16.94%
-239.56
+22.34%
-308.48
-143.30%
-126.79
Net Income From Continuing Operation Net Minority Interest
-198.97
+16.94%
-239.56
+22.34%
-308.48
-143.30%
-126.79
Net Income From Continuing And Discontinued Operation
-198.97
+16.94%
-239.56
+22.34%
-308.48
-143.30%
-126.79
Net Income Continuous Operations
-198.97
+16.94%
-239.56
+22.34%
-308.48
-143.30%
-126.79
Normalized Income
-222.81
+3.84%
-231.71
+24.37%
-306.37
-100.86%
-152.53
Net Income Common Stockholders
-198.97
+16.94%
-239.56
+22.34%
-308.48
-143.30%
-126.79
Diluted EPS
-3.46
+29.67%
-4.92
+23.96%
-6.47
-138.75%
-2.71
Basic EPS
-3.46
+29.67%
-4.92
+23.96%
-6.47
-138.75%
-2.71
Basic Average Shares
57.50
+18.20%
48.65
+2.05%
47.67
+2.00%
46.74
Diluted Average Shares
57.50
+18.20%
48.65
+2.05%
47.67
+2.00%
46.74
Diluted NI Availto Com Stockholders
-198.97
+16.94%
-239.56
+22.34%
-308.48
-143.30%
-126.79
Depreciation Amortization Depletion Income Statement
1.91
-9.48%
2.11
+2.88%
2.05
+73.67%
1.18
Depreciation And Amortization In Income Statement
1.91
-9.48%
2.11
+2.88%
2.05
+73.67%
1.18
Depreciation Income Statement
1.91
-9.48%
2.11
+2.88%
2.05
+73.67%
1.18
Gain On Sale Of PPE
6.00
0.00
0.00
—
Rent And Landing Fees
1.79
+31.89%
1.36
+50.89%
0.90
+9.76%
0.82
Rent Expense Supplemental
1.79
+31.89%
1.36
+50.89%
0.90
+9.76%
0.82
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
824.91
+48.22%
556.54
-33.08%
831.69
+17.98%
704.96
Current Assets
655.99
+68.08%
390.29
-40.13%
651.85
+36.72%
476.77
Cash Cash Equivalents And Short Term Investments
622.54
+69.39%
367.52
-40.52%
617.89
+75.12%
352.84
Cash And Cash Equivalents
80.24
-49.51%
158.93
-34.15%
241.36
+5.85%
228.01
Other Short Term Investments
542.30
+159.98%
208.59
-44.60%
376.53
+201.63%
124.83
Receivables
5.86
-0.31%
5.88
+40.26%
4.19
-95.90%
102.38
Accounts Receivable
5.86
-0.31%
5.88
+40.26%
4.19
-95.90%
102.38
Inventory
—
0.00
-100.00%
12.02
+73.66%
6.92
Raw Materials
—
0.00
-100.00%
7.16
+99.69%
3.58
Work In Process
—
0.00
-100.00%
4.11
+119.26%
1.87
Finished Goods
—
0.00
-100.00%
0.76
-48.29%
1.47
Prepaid Assets
20.51
+120.95%
9.28
-38.49%
15.09
+27.69%
11.82
Other Current Assets
7.08
-6.97%
7.61
+186.48%
2.65
-5.65%
2.81
Total Non Current Assets
168.92
+1.61%
166.25
-7.56%
179.84
-21.19%
228.19
Net PPE
26.32
-22.73%
34.07
-54.78%
75.34
-9.51%
83.26
Gross PPE
70.06
+6.59%
65.73
-49.83%
131.01
+2.85%
127.38
Accumulated Depreciation
-43.74
-38.16%
-31.66
+43.14%
-55.67
-26.17%
-44.13
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
4.36
+11.37%
3.91
-38.70%
6.38
+28.04%
4.99
Construction In Progress
—
0.00
-100.00%
5.67
+4.79%
5.41
Other Properties
37.52
+1.38%
37.01
-48.92%
72.45
+0.45%
72.12
Leases
28.19
+13.62%
24.81
-46.66%
46.51
+3.66%
44.87
Goodwill And Other Intangible Assets
98.14
+5.02%
93.46
+7.59%
86.86
+2.96%
84.36
Goodwill
25.36
+13.12%
22.41
-15.03%
26.38
+3.12%
25.58
Other Intangible Assets
72.79
+2.46%
71.04
+17.46%
60.48
+2.90%
58.78
Investments And Advances
30.24
+10.10%
27.46
+1160.39%
2.18
-94.55%
39.98
Other Investments
30.24
+10.10%
27.46
+1160.39%
2.18
—
Non Current Deferred Assets
8.65
-12.20%
9.86
-19.71%
12.28
-15.50%
14.53
Non Current Deferred Taxes Assets
8.65
-12.20%
9.86
-19.71%
12.28
-15.50%
14.53
Other Non Current Assets
5.56
+297.50%
1.40
-56.06%
3.18
-47.47%
6.06
Total Liabilities Net Minority Interest
626.01
+11.13%
563.29
-9.73%
624.02
+172.55%
228.96
Current Liabilities
62.92
+57.09%
40.05
-45.64%
73.67
-2.96%
75.92
Payables And Accrued Expenses
25.66
+48.02%
17.34
-10.73%
19.42
-20.26%
24.35
Payables
5.17
-28.46%
7.23
+9.73%
6.59
-40.04%
10.98
Accounts Payable
5.17
-28.46%
7.23
+9.73%
6.59
-40.04%
10.98
Current Accrued Expenses
20.49
+102.69%
10.11
-21.23%
12.83
-4.01%
13.37
Pensionand Other Post Retirement Benefit Plans Current
9.94
-19.11%
12.29
-24.43%
16.26
-5.45%
17.20
Current Debt And Capital Lease Obligation
3.86
+7.25%
3.60
-56.84%
8.34
-0.45%
8.38
Current Capital Lease Obligation
3.86
+7.25%
3.60
-56.84%
8.34
-0.45%
8.38
Current Deferred Liabilities
—
—
—
—
Current Deferred Revenue
—
—
—
—
Other Current Liabilities
23.46
+243.63%
6.83
-76.98%
29.65
+14.11%
25.98
Total Non Current Liabilities Net Minority Interest
563.09
+7.62%
523.24
-4.93%
550.34
+259.62%
153.04
Long Term Debt And Capital Lease Obligation
59.53
-4.69%
62.46
-51.98%
130.06
-3.30%
134.51
Long Term Debt
49.70
-3.17%
51.32
-49.56%
101.75
-1.01%
102.79
Long Term Capital Lease Obligation
9.83
-11.71%
11.14
-60.67%
28.32
-10.73%
31.72
Non Current Deferred Liabilities
7.97
+13.12%
7.04
-6.63%
7.54
-8.65%
8.26
Non Current Deferred Taxes Liabilities
7.97
+13.12%
7.04
-6.63%
7.54
-8.65%
8.26
Other Non Current Liabilities
495.59
+9.23%
453.73
+9.93%
412.74
+3919.24%
10.27
Stockholders Equity
198.90
+3045.81%
-6.75
-103.25%
207.67
-56.37%
476.01
Common Stock Equity
198.90
+3045.81%
-6.75
-103.25%
207.67
-56.37%
476.01
Capital Stock
3.69
+25.23%
2.94
+2.15%
2.88
+1.59%
2.84
Common Stock
3.69
+25.23%
2.94
+2.15%
2.88
+1.59%
2.84
Share Issued
62.53
+27.64%
48.99
+2.41%
47.83
+1.84%
46.97
Ordinary Shares Number
62.53
+27.64%
48.99
+2.41%
47.83
+1.84%
46.97
Additional Paid In Capital
1,582.37
+34.89%
1,173.07
+2.12%
1,148.75
+3.18%
1,113.39
Retained Earnings
-1,328.94
-17.61%
-1,129.96
-26.90%
-890.41
-53.01%
-581.93
Gains Losses Not Affecting Retained Earnings
-58.22
-10.27%
-52.80
+1.41%
-53.55
+8.13%
-58.29
Other Equity Adjustments
-58.22
-10.27%
-52.80
+1.41%
-53.55
+8.13%
-58.29
Total Equity Gross Minority Interest
198.90
+3045.81%
-6.75
-103.25%
207.67
-56.37%
476.01
Total Capitalization
248.60
+457.75%
44.57
-85.59%
309.42
-46.54%
578.80
Working Capital
593.07
+69.33%
350.24
-39.42%
578.18
+44.24%
400.86
Invested Capital
248.60
+457.75%
44.57
-85.59%
309.42
-46.54%
578.80
Total Debt
63.39
-4.04%
66.06
-52.27%
138.41
-3.14%
142.89
Capital Lease Obligations
13.69
-7.08%
14.74
-59.80%
36.66
-8.58%
40.10
Net Tangible Assets
100.76
+200.55%
-100.21
-182.95%
120.81
-69.15%
391.65
Tangible Book Value
100.76
+200.55%
-100.21
-182.95%
120.81
-69.15%
391.65
Held To Maturity Securities
—
—
0.00
-100.00%
39.98
Investmentin Financial Assets
—
—
0.00
-100.00%
39.98
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-177.96
+2.61%
-182.73
-25.22%
-145.93
-0.60%
-145.06
Cash Flow From Continuing Operating Activities
-177.96
+2.61%
-182.73
-25.22%
-145.93
-0.60%
-145.06
Net Income From Continuing Operations
-198.97
+16.94%
-239.56
+22.34%
-308.48
-143.30%
-126.79
Depreciation Amortization Depletion
14.76
+16.76%
12.64
+6.23%
11.90
+39.39%
8.54
Depreciation
14.76
+16.76%
12.64
+6.23%
11.90
+39.39%
8.54
Depreciation And Amortization
14.76
+16.76%
12.64
+6.23%
11.90
+39.39%
8.54
Other Non Cash Items
39.66
+109.50%
18.93
-57.29%
44.32
+647.98%
5.92
Stock Based Compensation
17.68
-20.57%
22.26
-36.57%
35.09
+2.60%
34.20
Deferred Tax
1.59
-34.62%
2.43
+26.44%
1.92
+230.68%
-1.47
Deferred Income Tax
1.59
-34.62%
2.43
+26.44%
1.92
+230.68%
-1.47
Operating Gains Losses
-35.42
-329.80%
15.41
+798.78%
-2.21
+90.01%
-22.08
Gain Loss On Investment Securities
-12.40
—
—
—
Net Foreign Currency Exchange Gain Loss
-23.02
-249.33%
15.41
+798.78%
-2.21
+90.01%
-22.08
Change In Working Capital
-6.79
-72.16%
-3.94
-104.78%
82.44
+290.02%
-43.38
Change In Receivables
-8.60
-283.28%
-2.24
-102.27%
98.68
+301.04%
-49.08
Changes In Account Receivables
-8.60
-283.28%
-2.24
-69.54%
-1.32
+67.60%
-4.08
Change In Inventory
0.00
-100.00%
2.42
+135.92%
-6.74
+2.66%
-6.92
Change In Payables And Accrued Expense
1.81
+143.84%
-4.12
+56.60%
-9.50
-175.24%
12.62
Change In Accrued Expense
4.47
+179.30%
-5.64
-5.89%
-5.33
-257.40%
3.38
Change In Payable
-2.67
-275.46%
1.52
+136.46%
-4.17
-145.13%
9.24
Change In Account Payable
-2.67
-275.46%
1.52
+136.46%
-4.17
-145.13%
9.24
Investing Cash Flow
-321.62
-297.35%
162.97
+179.23%
-205.69
-12.56%
-182.73
Cash Flow From Continuing Investing Activities
-321.62
-297.35%
162.97
+179.23%
-205.69
-12.56%
-182.73
Net PPE Purchase And Sale
-0.44
+96.24%
-11.69
-63.39%
-7.15
+59.55%
-17.69
Purchase Of PPE
-0.44
+96.24%
-11.69
-63.39%
-7.15
+59.55%
-17.69
Capital Expenditure
-0.44
+96.24%
-11.69
-63.39%
-7.15
+59.55%
-17.69
Net Investment Purchase And Sale
-321.18
-283.89%
174.66
+187.97%
-198.53
-21.69%
-163.15
Purchase Of Investment
-658.38
-82.96%
-359.84
+1.80%
-366.44
-124.61%
-163.15
Sale Of Investment
337.19
-36.91%
534.50
+218.33%
167.91
0.00
Net Business Purchase And Sale
—
0.00
0.00
+100.00%
-1.90
Purchase Of Business
—
0.00
0.00
+100.00%
-1.90
Net Intangibles Purchase And Sale
—
—
—
0.00
Purchase Of Intangibles
—
—
—
0.00
Financing Cash Flow
415.40
+798.31%
-59.49
-116.40%
362.72
+25001.80%
1.45
Cash Flow From Continuing Financing Activities
415.40
+798.31%
-59.49
-116.40%
362.72
+25001.80%
1.45
Net Issuance Payments Of Debt
0.00
+100.00%
-53.05
0.00
0.00
Issuance Of Debt
—
—
0.00
0.00
Repayment Of Debt
0.00
+100.00%
-53.05
0.00
0.00
Long Term Debt Issuance
—
—
0.00
0.00
Long Term Debt Payments
0.00
+100.00%
-53.05
0.00
0.00
Net Long Term Debt Issuance
0.00
+100.00%
-53.05
0.00
0.00
Net Common Stock Issuance
391.90
+18359.68%
2.12
+589.29%
0.31
-78.69%
1.45
Proceeds From Stock Option Exercised
23.50
0.00
0.00
—
Net Other Financing Charges
—
-8.56
-102.36%
362.41
—
Changes In Cash
-84.18
-6.23%
-79.25
-813.54%
11.11
+103.40%
-326.35
Effect Of Exchange Rate Changes
5.66
+213.85%
-4.97
-319.38%
2.27
+223.70%
-1.83
Beginning Cash Position
160.33
-34.44%
244.54
+5.78%
231.17
-58.67%
559.35
End Cash Position
81.80
-48.98%
160.33
-34.44%
244.54
+5.78%
231.17
Free Cash Flow
-178.40
+8.24%
-194.42
-27.00%
-153.08
+5.94%
-162.75
Interest Paid Supplemental Data
25.07
+21.89%
20.57
+21.86%
16.88
+82.52%
9.25
Amortization Of Securities
-10.46
+4.02%
-10.90
+0.15%
-10.92
0.00
Common Stock Issuance
391.90
+18359.68%
2.12
+589.29%
0.31
-78.69%
1.45
Issuance Of Capital Stock
391.90
+18359.68%
2.12
+589.29%
0.31
-78.69%
1.45
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category